Published in J Int Assoc Physicians AIDS Care (Chic) on June 01, 2007
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med (2007) 5.83
Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis (2004) 3.95
In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med (2013) 3.72
Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials (2007) 2.43
One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence (2010) 1.84
Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med (2009) 1.76
Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials (2002) 1.65
Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. J Infect (2009) 1.51
African sleeping sickness in tourists returning from Tanzania: the first 2 Italian cases from a small outbreak among European travelers. Clin Infect Dis (2001) 1.49
Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials (2002) 1.48
Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation. Transplantation (2008) 1.46
New times for an old disease: intracranial mass lesions caused by Mycobacterium tuberculosis in 5 HIV-negative African immigrants. Clin Infect Dis (2004) 1.40
Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients. Fundam Clin Pharmacol (2011) 1.38
Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr (2003) 1.28
Cluster of African trypanosomiasis in travelers to Tanzanian national parks. Emerg Infect Dis (2002) 1.28
The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J (2007) 1.26
Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr (2012) 1.25
Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) (2009) 1.24
Alkhurma hemorrhagic fever in travelers returning from Egypt, 2010. Emerg Infect Dis (2010) 1.22
Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood (2002) 1.22
Propionibacterium endocarditis: a case series from the International Collaboration on Endocarditis Merged Database and Prospective Cohort Study. Scand J Infect Dis (2007) 1.21
Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev (2002) 1.18
Increasing clinical virulence in two decades of the Italian HIV epidemic. PLoS Pathog (2009) 1.10
Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther (2003) 1.03
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. J Antimicrob Chemother (2009) 1.01
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS (2007) 0.99
CD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individuals. PLoS One (2010) 0.96
Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI). BMC Infect Dis (2014) 0.95
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS (2004) 0.94
CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS (2009) 0.93
Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3. Curr HIV Res (2010) 0.93
Brain abscess. N Engl J Med (2014) 0.92
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol (2011) 0.91
Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy. AIDS Res Hum Retroviruses (2011) 0.90
Nosocomial bloodstream infections among human immunodeficiency virus-infected patients: incidence and risk factors. Clin Infect Dis (2002) 0.89
Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. J Antimicrob Chemother (2005) 0.88
Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use. Drugs (2012) 0.88
Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients. J Clin Pharmacol (2011) 0.86
Predictors of AIDS-defining events among advanced naïve patients after HAART. HIV Clin Trials (2007) 0.86
Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. J Antimicrob Chemother (2007) 0.86
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy. J Clin Lab Anal (2002) 0.86
Images in cardiovascular medicine. Bacterial pericarditis due to Providencia stuartii: an atypical case of relapsing pericarditis. Circulation (2010) 0.85
Abacavir-induced liver toxicity in an HIV-infected patient. AIDS (2014) 0.85
Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor. Expert Rev Anti Infect Ther (2013) 0.85
Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit (2010) 0.84
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. Antivir Ther (2010) 0.84
Mefloquine versus quinine plus sulphalene-pyrimethamine (metakelfin) for treatment of uncomplicated imported falciparum malaria acquired in Africa. Antimicrob Agents Chemother (2005) 0.83
Back to the ring: knocking-out headache. Neurol Sci (2011) 0.83
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen. BMC Med Inform Decis Mak (2011) 0.82
Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. AIDS (2015) 0.82
Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. AIDS (2008) 0.82
Once-a-day HAART: dream or reality? HIV Clin Trials (2003) 0.82
Aetiological diagnosis in acute and recurrent pericarditis: when and how. J Cardiovasc Med (Hagerstown) (2009) 0.81
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. J Hepatol (2004) 0.81
When phylogenetic analysis complements the epidemiological investigation: a case of HIV-2 infection, Italy. New Microbiol (2013) 0.79
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. J Antimicrob Chemother (2007) 0.79
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3. Antivir Ther (2007) 0.78
The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens. Antivir Ther (2006) 0.78
Hepatitis C infection increases the risk of the modification of first highly active antiretroviral therapy in HIV-infected patients. AIDS (2004) 0.78
Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort. HIV Clin Trials (2007) 0.77
Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Clin Infect Dis (2003) 0.77